Arcutis Biotherapeutics, Inc. ARQT Change in Accrued Liabilities
Change in Accrued Liabilities at other companies
Other financials
Where this comes from
Reported directly by Arcutis Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilities.
The official record: Arcutis Biotherapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arcutis Biotherapeutics, Inc.'s change in accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arcutis Biotherapeutics, Inc.'s change in accrued liabilities?
- Arcutis Biotherapeutics, Inc. (ARQT) reported change in accrued liabilities of $20.77M in Q1 2026.
- How has Arcutis Biotherapeutics, Inc.'s change in accrued liabilities changed year-over-year?
- Arcutis Biotherapeutics, Inc.'s change in accrued liabilities increased by 9804.7% year-over-year, from -$214K to $20.77M.
- What is the long-term trend for Arcutis Biotherapeutics, Inc.'s change in accrued liabilities?
- Over 4 years (2021 to 2025), Arcutis Biotherapeutics, Inc.'s change in accrued liabilities has grown at a 47.9% compound annual growth rate (CAGR), from $10.46M to $50.04M.
- What does change in accrued liabilities mean?
- Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.